Beam Therapeutics Inc.

NASDAQ:BEAM

Biotechnology

Healthcare
$21.01 +1.46%

+$0.48 today

Market cap
$2.17B
Beta
2.20
P/E (TTM)
-52.3
EPS (TTM)
-$0.63
52W Low $15.60High $36.44

Volume 4.86M

Average 2.11M

BEAM Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Beam Therapeutics Inc.NASDAQ: BEAM

Weighted Avg Shares · Q2 FY2026 · quarter ended Jun 2026

Weighted avg shares grows, but more slowly than its trailing trend

Q2 FY2026 weighted avg shares of 104.33M shares rose 2.3% year over year, behind the +16.4% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 1.0% from the prior quarter. Over 3 fiscal years it compounded at +12.2% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +2.3% toward the trailing-twelve-month pace of +16.4%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
104.33M+1.0% QoQ
Last fiscal yearDec 2025
98.91M+20.2% YoY
LTMJun 2026
103.26M+16.4% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+2.3%——
1 year+20.2%——
3-year CAGR+12.2%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
98.91M USD
Year-over-year change
+20.2%
4-year CAGR
+11.4%

Weighted Avg Shares vs competitors

How BEAM compares with its peers on the latest reported figures

  • BEAM's LTM Jun 2026 weighted avg shares of 103.26M shares is the 4th highest of the 9 companies compared; the peer median is 97.59M shares.
  • Its year-over-year change of +16.4% is the 2nd highest of 9, against a peer median of +8.8%.
  • Over three fiscal years its annual growth of +12.2% compares with a peer median of +13.7%.
BEAM Competitors Peer median
Weighted Avg Shares for BEAM and competitors
Company Period LTM YoY 3-year CAGR
ALLOAllogene Therapeutics, Inc.LTM Mar 2026225.47M +9.3%+15.5%
FATEFate Therapeutics, Inc.LTM Mar 2026119.09M +1.0%+7.1%
NTLAIntellia Therapeutics, Inc.LTM Mar 2026110.2M +9.3%+12.1%
BEAMBeam Therapeutics Inc.LTM Jun 2026103.26M +16.4%+12.2%
CLLSCellectis S.A.LTM Mar 2026100.38M +2.9%+30.1%
CRSPCRISPR Therapeutics AGLTM Sep 202694.81M +8.4%+5.0%
CRBUCaribou Biosciences, Inc.LTM Mar 202694.18M +3.6%+15.4%
EDITEditas Medicine, Inc.LTM Mar 202690.28M +9.3%+8.9%
DTILPrecision BioSciences, Inc.LTM Mar 202612.13M +61.6%+63.6%
Peer median (excluding BEAM) 97.59M+8.8%+13.7%

Competitors are the stored peer set for BEAM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue51.84M60.92M377.71M63.52M139.74M
Cost of Revenue232.13M311.59M0367.56M22.29M
Gross Profit(180.29M)(250.67M)377.71M(304.04M)117.45M
Gross Margin-347.8%-411.5%100.0%-478.7%84.0%
Research & Development387.09M311.59M437.38M367.56M409.62M
Selling, General & Admin57.22M87.81M116.81M111.53M113.82M
Operating Expenses212.18M87.81M554.19M111.53M501.14M
Depreciation & Amortization7.45M14.15M20.01M21.93M22.29M
EBITDA(230.06M)(271.53M)(111.15M)(354.78M)(13.97M)
EBITDA Margin-443.8%-445.7%-29.4%-558.5%-10.0%
Operating Income(392.47M)(338.48M)(176.49M)(415.57M)(383.69M)
Operating Margin-757.0%-555.6%-46.7%-654.3%-274.6%
Interest Income015.3M46.68M49.09M0
Interest Expense000043.73M
Other Income / Expenses21.83M52.8M45.32M38.87M303.7M
Income Before Tax(370.64M)(285.68M)(131.16M)(376.7M)(79.99M)
Pre-Tax Margin-714.9%-468.9%-34.7%-593.1%-57.2%
Income Tax Expense03.41M1.37M39K0
Net Income(370.64M)(289.09M)(132.53M)(376.74M)(79.99M)
Net Margin-714.9%-474.5%-35.1%-593.1%-57.2%
EPS (Basic)(5.77)(4.13)(1.72)(4.58)(0.81)
EPS (Diluted)(5.77)(4.13)(1.72)(4.58)(0.81)
Weighted Avg Shares64.23M70.02M77.15M82.31M98.91M
Weighted Avg Shares (Diluted)64.23M70.02M77.15M82.31M98.91M

Beam Therapeutics Inc.

NASDAQ:BEAM

Intrinsic Alpha fair value

Locked

Current Price

$21.01

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.